ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

VP, Learning & Leadership Development at Dyne Therapeutics - ApplyBlast

VP, Learning & Leadership Development

Dyne Therapeutics

3 months ago

4.1 on Glassdoor

Waltham, MA

Onsite

Full Time

Executive

1 applicant

View Job Listing

Apply to 100+ jobs

About this role

The VP of Learning & Leadership Development is a strategic executive responsible for designing and executing Dyne's enterprise-wide leadership, management, and workforce capability strategy. This role defines the company's learning philosophy, establishes training systems and standards, and partners with the Executive Committee to drive organizational performance and talent growth. The position involves building leadership pipelines, managing the Learning & Leadership Development function, and integrating training across all functional areas to support commercialization and global expansion.

Responsibilities

Develop and execute multi-year enterprise leadership development strategies
Build leadership pipelines for critical business, scientific, and commercial roles
Design scalable learning solutions blending instructor-led and digital methodologies
Partner with executive teams to strengthen leadership effectiveness and alignment
Manage budgets and vendor relationships for the Learning & Leadership Development function

Skills

Qualifications

Bachelor's degreeAdvanced degree preferred

About Dyne Therapeutics

dyne-tx.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2018

View Profile

Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.